Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Early trial results in lung cancer

Early trial results in lung cancer

NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

DME treatment evolves in favour of intravitreal anti-VEGF injections

DME treatment evolves in favour of intravitreal anti-VEGF injections

Low BMI linked to poorer survival in advanced colorectal cancer

Low BMI linked to poorer survival in advanced colorectal cancer

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

No overall survival benefit for bevacizumab in ovarian cancer

No overall survival benefit for bevacizumab in ovarian cancer

Growth of lymph node metastases takes advantage of existing blood vessels

Growth of lymph node metastases takes advantage of existing blood vessels

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

SIRFLOX study promises better and earlier treatment option for liver cancer patients

SIRFLOX study promises better and earlier treatment option for liver cancer patients

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Study could offer new way to treat, prevent diabetes-associated blindness

Study could offer new way to treat, prevent diabetes-associated blindness

No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD